StockData
Novo Nordisk A S logo

Novo Nordisk A S (NVO) stock

NVONYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NONOF
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$39.43−1.27 (-3.12%)

Close on Nov 18, 2026Market cap $176.06BP/E 11.6Yield –

Novo Nordisk A S revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2025 it was 309.06B DKK, up 6.4% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is 309.06B DKK in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025309.06B DKK+6.4%
FY2024Dec 31, 2024290.40B DKK+25.0%
FY2023Dec 31, 2023232.26B DKK+31.3%
FY2022Dec 31, 2022176.95B DKK+25.7%
FY2021Dec 31, 2021140.80B DKK+10.9%
FY2020Dec 31, 2020126.95B DKK+4.0%
FY2019Dec 31, 2019122.02B DKK+9.1%
FY2018Dec 31, 2018111.83B DKK+0.1%
FY2017Dec 31, 2017111.70B DKK-0.1%
FY2016Dec 31, 2016111.78B DKK+3.6%
FY2015Dec 31, 2015107.93B DKK–

More Novo Nordisk A S figures

See a number that looks wrong?